Featured Abstracts
Review key findings and research highlights presented at major industry conferences and events.
Featured Content
Cureus competition winner
A Primary Liver Cancer Patient Treated With Stereotactic Body Radiation Therapy Using Diaphragm Motion Surrogate Tracking in CyberKnife
cureus competition winner
Commissioning Tests of Radixact Synchrony Using Patient-Specific 3D-Printed Lung Phantom Inserts
cureus competition winner
A Case of a 12-cm Huge Hepatocellular Carcinoma Treated Successfully With Two-Stage CyberKnife Stereotactic Body Radiation Therapy
Featured Case Studies
Transition to the Radixact® System for Pediatric Total Body Irradiation (TBI) Treatment
A 6-year-old boy presented with a high white blood cell count and a mediastinal mass. He was diagnosed with high-risk T-cell acute lymphoblastic leukemia (ALL) and treated in the ALLTogether1 trial1. During induction therapy with regimen B, the patient continued to have high levels of minimal residual disease (MRD). Subsequently,
Precision and Innovation: Insights on a robust radiation oncology practice from a long-term CyberKnife® System user
According to the World Health Organization, in 2050 more than 35 million new cancer cases will be diagnosed, a 77 percent increase from the estimated 20 million cases in 20221. Men are anticipated to be the hardest hit, with a study in the journal Cancer finding that global cancer cases
Deep Inspiration Breath Hold Using VitalHold™ on the Radixact® System
A 45-year-old female patient was diagnosed with pT2N1M0 invasive ductal carcinoma of the left breast. The patient underwent breast conservation surgery with axillary dissection, followed by chemotherapy and radiation therapy. Radiation therapy was delivered by the Radixact® System, the latest generation of the TomoTherapy® Platform with surface guided radiotherapy (SGRT)
1021: RE-START: A National Registry Including Patients Undergoing Reirradiation After Previous RT for Prostate Cancer. A Study on Behalf of AIRO
Giulio Francolini et al. | ESTRO | 2025
